Home / Health / Oklahoma doctors reveal revolutionary cancer treatment

Oklahoma doctors reveal revolutionary cancer treatment



Oklahoma doctors on Wednesday revealed what they call a revolutionary new treatment for cancer patients. The treatment utilizes the body's own immune cells to fight tumors, and it will be offered from Thursday at the Stephenson Cancer Center at OU Medicine. CAR T cell therapy has been approved by the Food and Drug Administration. Officials said the first use is for two different blood cancers, one affecting children and the other affecting adults. "CAR T is a major breakthrough for patients who have not improved with standard treatments," says Dr. George Selby, Head of the Transplant and Cell Therapy Program at Stephenson Cancer Center. "It's an immunotherapy where we use our own cells to recognize cancer cells. That's what a normal immune system does ̵

1; it works in monitoring capacity so that when a malignant cell occurs, it is killed by our immune system. CAR T is a way to" restart the "immune system when it has failed." CAR T will initially be used to treat advanced lymphoma in adults. In the coming months, doctors predict to offer similar treatment for acute lymphoblastic lymphoma in children and young adults. In either case, patients must have failed to respond to standard chemotherapy or stem cell transplantation. CAR T stands for treatment with chimeric antigen receptor T cell. Patients treated with CAR T will first have their blood collected at the Oklahoma Blood Institute in a process similar to a typical blood donation. T cells, a type of white blood cell that are involved in immunity, are filtered off and plasma and red cells are returned to the patient. The T cells are then sent to a company that injects them with the gene for a chimeric antigen receptor, which is known to bind to cancer cells and activate the T cell, according to hospital officials. This process allows the newly developed T cells to recognize and attack cancer with remarkable efficiency. When the CAR T cells are generated, they are returned to the Stephenson Cancer Center and given to the patient through an IV, just like a blood transfusion, officials said. "Until the advent of CAR T, if a patient's tumor came back after a stem cell transplant, their options were very limited if they existed at all," Selby said. "This is a major breakthrough for those patients for whom standard treatment has not succeeded." Unlike other types of cancer therapies, CAR T is a one-time treatment, officials said. The T cells remain in the body and if cancer returns, the cells reactivate to attack the tumors. "These T cells continue to kill hundreds to thousands of tumor cells; the nickname of these cells is" serial killer ", says Dr. Adam Asch, Deputy Director of Stephenson Cancer Center and Head of the Medical Oncology and Hematology Department. Cancer has been the sacred degree for oncologists, Sa Asch. "Research data leading to the approval of CAR T has been extraordinary," said Asch. "This treatment appears to be prolonged in a high proportion of these patients." According to officials, clinical trials are on The way to study the effectiveness of CAR T in the treatment of other blood cancers, including multiple myeloma, as well as solid tumors.Another study will study the effectiveness of CAR T over transplantation; CAR T may potentially go before the transplant as a treatment due to its ability to use the patient's own immune system instead of someone else's. Stephenson Cancer The Center will participate in several such clinical trials.

Oklahoma doctors on Wednesday revealed what they call a revolutionary new treatment for cancer patients.

The treatment utilizes the body's own immune cells to fight tumors, and it will be offered from Thursday at the Stephenson Cancer Center at OU Medicine.

CAR T cell therapy has been approved by the Food and Drug Administration. Officials said the first use is for two different blood cancers, one affecting children and the other affecting adults.

"CAR T is a major breakthrough for patients who have not improved with standard treatments," says Dr. George Selby, Head of the Transplant and Cell Therapy Program at Stephenson Cancer Center. "It's an immunotherapy where we use our own cells to recognize cancer cells. That's what a normal immune system does – it works in monitoring capacity so that when a malignant cell occurs, it is killed by our immune system. CAR T is a way to" restart the "immune system once it has failed." CAR T will initially be used to treat advanced lymphoma in adults. In the coming months, doctors predict to offer similar treatment for acute lymphoblastic lymphoma in children and young adults. In either case, patients must have failed to respond to standard chemotherapy or stem cell transplantation. CAR T stands for T cell therapy of chimeric antigen receptor. Patients treated with CAR T will first have their blood collected at the Oklahoma Blood Institute in a process similar to a typical blood donation. T cells, a type of white blood cell that are involved in immunity, are filtered off and plasma and red cells are returned to the patient. The T cells are then sent to a company that injects them with the gene for a chimeric antigen receptor, which is known to bind to cancer cells and activate the T cell, according to hospital officials.

This process allows the newly developed T cells to recognize and attack cancer with remarkable efficiency. When the CAR T cells are generated, they are returned to the Stephenson Cancer Center and given to the patient through an IV, just like a blood transfusion, officials said.

"Until the advent of CAR T, if a patient's tumor came back after a stem cell transplant, their options were very limited if they existed at all," Selby said. "This is a major breakthrough for those patients for whom standard treatment has not succeeded."

Unlike other types of cancer therapies, CAR T is a one-time treatment, officials said. The T cells remain in the body, and if cancer recurs, the cells reactivate to attack the tumors.

"These T cells continue to kill hundreds to thousands of tumor cells; the nickname of these cells is" serial killer ", said Dr. Adam Asch, Deputy Director of Stephenson Cancer Center and Head of the Medical Oncology and Hematology Division.

The use of the immune system to fight cancer has been the holy grail of oncologists, Asch said.

"Research data leading to the approval of CAR T has been extraordinary," said Asch. "This therapy appears to be prolonged in a high proportion of these.

According to officials, clinical trials are underway to investigate the efficacy of CAR T in the treatment of other blood cancer, including multiple myeloma, as well as solid tumors.Another study will study the efficacy of CAR T over transplantation; be able to go before the transplant as a treatment because of its ability to use the patient's own immune system instead of f is anyone else's. Stephenson Cancer Center will participate in a number of clinical trials.

AlertMe


Source link